| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/01/2001 | CA2689694A1 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 02/01/2001 | CA2396591A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 02/01/2001 | CA2383690A1 29 human secreted proteins |
| 02/01/2001 | CA2382757A1 Carboxylic acid derivatives and adhesion molecule inhibitors which contain the same as effective ingredients |
| 02/01/2001 | CA2380317A1 Human synthetases |
| 02/01/2001 | CA2380270A1 26 human prostate and prostate cancer associated proteins |
| 02/01/2001 | CA2380226A1 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | CA2380218A1 Novel thiazine or pyrazine derivatives |
| 02/01/2001 | CA2380192A1 Oligonucleotides for inhibiting the expression of human eg5 |
| 02/01/2001 | CA2380176A1 Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical |
| 02/01/2001 | CA2380037A1 Vgf polypeptides and methods of treating vgf-related disorders |
| 02/01/2001 | CA2379863A1 Kinase blocking polypeptides and uses thereof |
| 02/01/2001 | CA2379818A1 Catalytic anti-factor viii allo-antibodies |
| 02/01/2001 | CA2379802A1 Drosophila recombination-associated protein and methods for use |
| 02/01/2001 | CA2379801A1 Receptors and associated proteins |
| 02/01/2001 | CA2379784A1 Cell cycle and proliferation proteins |
| 02/01/2001 | CA2379777A1 Isolated peptide of the horny layer and use thereof |
| 02/01/2001 | CA2379659A1 Antisense modulation of pten expression |
| 02/01/2001 | CA2379251A1 Highly purified cytokine activating factor and methods of use |
| 02/01/2001 | CA2379241A1 Peptides containing n-substituted d-amino acids for preventing beta-strand association |
| 02/01/2001 | CA2378953A1 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 02/01/2001 | CA2378849A1 Apicidin-derived cyclic tetrapeptides |
| 02/01/2001 | CA2378845A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 02/01/2001 | CA2378779A1 Peptides containing n-substituted l-amino acids for preventing beta-strand association |
| 02/01/2001 | CA2378776A1 Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases |
| 02/01/2001 | CA2378760A1 Composition and method for enhancing wound healing |
| 02/01/2001 | CA2378473A1 Modulation of platelet activation |
| 02/01/2001 | CA2378462A1 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | CA2378403A1 Novel polynucleotides and method for the use thereof |
| 02/01/2001 | CA2378328A1 Method of promoting bone growth with hyaluronic acid and growth factors |
| 02/01/2001 | CA2376961A1 Lactam inhibitors of hepatitis c virus ns3 protease |
| 02/01/2001 | CA2376465A1 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 02/01/2001 | CA2375650A1 Ehrlichia canis genes and vaccines |
| 02/01/2001 | CA2375571A1 Human nervous system-associated proteins |
| 02/01/2001 | CA2345920A1 Use of interleukin-11 to treat gastrointestinal disorders |
| 01/31/2001 | EP1072682A1 Protein and gene participating in the differentiation of immortalized cells |
| 01/31/2001 | EP1072681A2 Human-keratinocytes regulator protein pKe#165 |
| 01/31/2001 | EP1072610A1 Novel cytokine-like protein |
| 01/31/2001 | EP1072609A2 Cytoprotective agents comprising prosaposin-related peptides |
| 01/31/2001 | EP1072608A1 Glutathione derivatives and dosage forms thereof |
| 01/31/2001 | EP1072273A1 Vascularization inhibitors |
| 01/31/2001 | EP1072271A2 Selective immune down regulation (SIDR) mediated transplantation processes |
| 01/31/2001 | EP1072270A2 Botulinum toxins for treating dystonia |
| 01/31/2001 | EP1072255A2 Desferrioxamine oral delivery system |
| 01/31/2001 | EP1071955A1 Improved immunodiagnostic assays using reducing agents |
| 01/31/2001 | EP1071939A1 Molecular sensing apparatus and method |
| 01/31/2001 | EP1071822A2 Fetal testing for prediction of low birth weight |
| 01/31/2001 | EP1071806A2 Materials and methods for gene therapy |
| 01/31/2001 | EP1071805A2 Adenoviral vectors for treating disease |
| 01/31/2001 | EP1071795A1 Canine erythropoietin gene and recombinant protein |
| 01/31/2001 | EP1071794A1 A method for inhibiting tumor invasion or spreading in a subject |
| 01/31/2001 | EP1071792A2 Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins |
| 01/31/2001 | EP1071787A1 Tao protein kinases and methods of use |
| 01/31/2001 | EP1071784A1 Polypeptides from moraxella (branhamella) catarrhalis |
| 01/31/2001 | EP1071783A2 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis |
| 01/31/2001 | EP1071781A1 B-cell growth factor related protein |
| 01/31/2001 | EP1071780A1 Soluble protein ztmpo-1 |
| 01/31/2001 | EP1071777A2 Human nucleic acid sequences of normal uterus tissue |
| 01/31/2001 | EP1071776A2 Human nucleic acid sequences of normal bladder tissue |
| 01/31/2001 | EP1071775A2 Human nucleic acid sequences of endometrium tumour tissue |
| 01/31/2001 | EP1071774A2 Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof |
| 01/31/2001 | EP1071772A2 Fizz proteins |
| 01/31/2001 | EP1071771A2 Gene encoding syntaxin interacting protein |
| 01/31/2001 | EP1071770A2 Glaucoma therapeutics and diagnostics based on a novel human transcription factor |
| 01/31/2001 | EP1071768A1 Delivery of therapeutic proteins via implantation of genetically modified cells in the omentum |
| 01/31/2001 | EP1071767A1 Gene coding for heliomicine and use thereof |
| 01/31/2001 | EP1071766A1 HUMAN G-PROTEIN COUPLED RECEPTOR GPR6sb |
| 01/31/2001 | EP1071765A1 Alk-1 responds to tgf-beta and signals through smad-1 and smad-5 |
| 01/31/2001 | EP1071764A1 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN $g(a) v?-SUBUNIT EXPRESSION |
| 01/31/2001 | EP1071759A1 Assay methods for modulators of hematopoietic cell phosphatase |
| 01/31/2001 | EP1071755A1 Human bile salt-stimulated lipase (bssl) obtainable from transgenic sheep |
| 01/31/2001 | EP1071753A2 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| 01/31/2001 | EP1071752A1 CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| 01/31/2001 | EP1071749A1 Novel lrsg protein and nucleic acid molecules and uses therefor |
| 01/31/2001 | EP1071718A1 Matrix binding factor |
| 01/31/2001 | EP1071717A1 Mutagenized il13-based chimeric molecules |
| 01/31/2001 | EP1071715A2 TRANSFERRIN RECEPTOR GENES OF $i(MORAXELLA) |
| 01/31/2001 | EP1071713A2 Srebp-1 and srebp-2 in a phosphorylated form |
| 01/31/2001 | EP1071712A1 Sp22, a fertility-associated protein from sperm and a method for evaluating and affecting male fertility using it |
| 01/31/2001 | EP1071709A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 01/31/2001 | EP1071708A1 Edg family gene, human h218 |
| 01/31/2001 | EP1071707A1 Novel omega conotoxin peptides |
| 01/31/2001 | EP1071704A1 Novel matrix metalloproteinase inhibitors and down-regulators |
| 01/31/2001 | EP1071699A1 Enhanced antisense modulation of icam-1 |
| 01/31/2001 | EP1071696A1 Programmed cell death and caspase-12 |
| 01/31/2001 | EP1071694A1 Staphylococcus aureus spo0j2: polynucleotide and protein |
| 01/31/2001 | EP1071485A2 Revascularization apparatus having coaxial channeling and injection means |
| 01/31/2001 | EP1071472A1 Peptides for efficient gene transfer |
| 01/31/2001 | EP1071470A1 COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN DELIVERY TO ANTIGEN PRESENTING CELLS $i(IN VIVO) |
| 01/31/2001 | EP1071469A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
| 01/31/2001 | EP1071468A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 01/31/2001 | EP1071460A1 INTERNALIZING ErbB2 ANTIBODIES |
| 01/31/2001 | EP1071459A1 Methods to provoke anti-cancer immune responses |
| 01/31/2001 | EP1071456A1 Vaccines with an ltb adjuvant |
| 01/31/2001 | EP1071452A1 Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof |
| 01/31/2001 | EP1071451A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 01/31/2001 | EP1071450A2 Combination of antigen pulsed apcs and interleukin 12 for tumour and viral therapy |
| 01/31/2001 | EP1071449A2 Antagonists of the inflammatory mediator oncostatin m (osm) |
| 01/31/2001 | EP1071448A1 Use of protease inhibitors for treating skin wounds |
| 01/31/2001 | EP1071447A1 Treatment for diabetes |